ÐÂÎÅÖÐÐÄ
News Center
ÕæʵÌìÏÂÑо¿Á¦Ö¤£¡°²ÂÞÌæÄá¡°ÔÙÌôÕ½¡±Õ½ÂÔΪÈí×éÖ¯ÈâÁö»¼ÕßÖþÀηÀµØ
Ðû²¼Ê±¼ä£º2025-03-27
¿ËÈÕ £¬£¬ £¬£¬£¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾£¨1177.HK£©ÏÂÊôÆóÒµÕý´óÌìÇç1ÀàÁ¢ÒìÒ©°²ÂÞÌæÄáÔÙÌôսǰÏß¾°²ÂÞÌæÄáÖÎÁƺóÏ£ÍûµÄÍíÆÚÈí×éÖ¯ÈâÁö£¨STS£©Ñо¿ £¬£¬ £¬£¬£¬ÁÁÏà2025ÄêESMOÈâÁö¼°ÓÐÊýÖ×Áö´ó»á£¨ESMO SRCC£©Ð¡ÐÍ¿ÚÍ·±¨¸æ¡£¡£¡£¡£¡£¡£Ñо¿ÌáÐÑ £¬£¬ £¬£¬£¬°²ÂÞÌæÄáÔÙÌôÕ½ÓÐÍû³ÉΪÀÒ°±ËἤøÒÖÖƼÁ£¨TKIs£©ÄÍÒ©ÍíÆÚSTS»¼ÕßеÄÖÎÁÆÑ¡Ôñ £»£» £»£»£»£»£»£»¹ØÓÚ·ÇÏÙÅÝ×´Èí×éÖ¯ÈâÁö£¨ASPS£©»¼Õß £¬£¬ £¬£¬£¬ÔÙÌôÕ½½×¶ÎÓ¦Óð²ÂÞÌæÄáÍŽữÁÆÏÔʾ³ö¸üÓÅDZÁ¦
°ÐÏòÖÎÁƵÄÐËÆ𠣬£¬ £¬£¬£¬ÓÈÆäÒÔÀÒ°±ËἤøÒÖÖƼÁ£¨TKIs£©Îª´ú±íµÄ°ÐÏòÒ©ÎïÈÃÍíÆÚÈí×éÖ¯ÈâÁö£¨STS£©»¼Õß»ñµÃÁ˸üºÃµÄÉúÑÄ¡£¡£¡£¡£¡£¡£Ö»¹Ü³õʼÁÆЧÏÔÖø £¬£¬ £¬£¬£¬µ«Ëæ×Åʱ¼äµÄÍÆÒÆ»¼Õ߻ᱬ·¢TKIsÄÍÒ©¡£¡£¡£¡£¡£¡£È»¶ø £¬£¬ £¬£¬£¬ÔÚά³ÖѪ¹ÜÄÚƤÉú³¤Òò×ÓÊÜÌ壨VEGFR£©Í¨Â·Ò»Á¬ÒÖÖƵÄÇéÐÎÏ £¬£¬ £¬£¬£¬Í¨¹ý²î±ðµÄÖÎÁÆ·½·¨ÍŽáTKIsÈÔ¿ÉÄÜ´øÀ´ÖÎÁÆ»ñÒæ¡£¡£¡£¡£¡£¡£°²ÂÞÌæÄáÊÇÒ»ÖÖÐÂÐÍTKI £¬£¬ £¬£¬£¬¿ÉÒÖÖÆVEGFR 1-3¡¢PDGFR α/β¡¢FGFR 1-4¡¢c-KitµÈ°Ðµã¼°¼¤Ã¸¡£¡£¡£¡£¡£¡£±¾Ñо¿Ö¼ÔÚÆÀ¹À°²ÂÞÌæÄá×÷ΪÔÙÌôÕ½¼Æ»®ÔÚÇ°Ïß¾°²ÂÞÌæÄáÖÎÁƺóÏ£ÍûµÄÍíÆÚÈí×éÖ¯ÈâÁö»¼ÕßµÄÁÆЧÓëÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£
Ñо¿»ØÊ×ÐÔÆÊÎöÁË2019Äê7ÔÂÖÁ2023Äê3ÔÂÖйú4¼ÒÈâÁöÖÐÐÄÊÕÖεÄÍíÆÚSTS»¼Õß²¡Àú¡£¡£¡£¡£¡£¡£¹²É¸Ñ¡295ÀýÇ°Ïß½ÓÊÜ°²ÂÞÌæÄáÖÎÁÆÏ£ÍûºóÔٴνÓÊܺ¬°²ÂÞÌæÄáÍŽá¼Æ»®ÖÎÁƵľֲ¿ÍíÆÚ»òתÒÆÐÔSTS»¼Õß £¬£¬ £¬£¬£¬×îÖÕ217Àý»¼ÕßÁÆЧ¿ÉÆÀ¹À £¬£¬ £¬£¬£¬ÖÐλÄêËêΪ61Ë꣨¹æÄ£26-88Ë꣩¡£¡£¡£¡£¡£¡£Ö÷Òª²¡ÀíÑÇÐÍ°üÀ¨£ºÆ½»¬¼¡ÈâÁö£¨16.13%£©¡¢Ö¬·¾ÈâÁö£¨14.75%£©¡¢Î´·Ö½â¶àÐÎÐÔÈâÁö£¨14.75%£©¡¢ÏÙÅÝ×´Èí×éÖ¯ÈâÁö£¨ASPS £¬£¬ £¬£¬£¬13.82%£©¡¢»¬Ä¤ÈâÁö£¨11.52%£©¼°ÆäËû£¨29.03%£©¡£¡£¡£¡£¡£¡£
Ñо¿Êý¾ÝÏÔʾ £¬£¬ £¬£¬£¬ÖÐλËæ·Ã7.75¸öÔ £¬£¬ £¬£¬£¬ÖÐλÎÞÏ£ÍûÉúÑÄÆÚ£¨PFS£©Îª4.17¸öÔ £¬£¬ £¬£¬£¬ÖÐλ×ÜÉúÑÄÆÚ£¨OS£©ÉÐδµÖ´ï £¬£¬ £¬£¬£¬6¸öÔºÍ12¸öÔÂOSÂÊ»®·ÖΪ91.40%ºÍ70.24% £¬£¬ £¬£¬£¬¼²²¡¿ØÖÆÂÊ£¨DCR£©Îª72.81%[1]¡£¡£¡£¡£¡£¡£ÓÉÓÚASPSÊôÓÚ»¯ÁƼ«²»Ãô¸ÐÑÇÐÍ £¬£¬ £¬£¬£¬Òò´ËÑо¿¾ÙÐÐÁËASPSºÍ·ÇASPSÑÇ×éÆÊÎö¡£¡£¡£¡£¡£¡£·ÇASPS»¼ÕßÖÐ £¬£¬ £¬£¬£¬°²ÂÞÌæÄáÍŽữÁÆ£¨n=65£©ÖÐλPFSΪ5.10¸öÔ £¬£¬ £¬£¬£¬°²ÂÞÌæÄáÍŽáÃâÒßÖÎÁÆ£¨n=86£©Îª4.03¸öÔ £¬£¬ £¬£¬£¬°²ÂÞÌæÄáÍŽữÁƼ°ÃâÒßÖÎÁÆ£¨n=36£©Îª4.13¸öÔ £»£» £»£»£»£»£»£»DCR»®·ÖΪ76.92%¡¢72.09%ºÍ72.22%[1]¡£¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
[1] J Chen,et al. Rechallenge of Anlotinib in Patients with Advanced Soft Tissue Sarcoma After Progression on Prior Anlotinib Treatment: A Multicenter Retrospective Study. 2025 ESMO SRCC, 63MO.
ÉùÃ÷£º
1.ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷ £¬£¬ £¬£¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ £¬£¬ £¬£¬£¬·Ç¹ã¸æÓÃ;¡£¡£¡£¡£¡£¡£
2.±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£¡£¡£¡£¡£¡£
3.±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼ £¬£¬ £¬£¬£¬²»¿ÉÒÔÈκη½·¨È¡´úרҵµÄÒ½ÁÆÖ¸µ¼ £¬£¬ £¬£¬£¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£¡£¡£¡£¡£¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢ £¬£¬ £¬£¬£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£¡£¡£¡£¡£¡£